TY - JOUR
T1 - Characterizing crosstalk in epigenetic signaling to understand disease physiology
AU - Lempiäinen, Joanna K.
AU - Garcia, Benjamin A.
N1 - Funding Information:
J.K.L was supported by the Sigrid Jusélius Foundation and the Maud Kuistila Foundation. This work was supported by the National Institutes of Health (NIH) grants HD106051, CA196539 and AI118891.
Publisher Copyright:
© 2023 The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Epigenetics, the inheritance of genomic information independent of DNA sequence, controls the interpretation of extracellular and intracellular signals in cell homeostasis, proliferation and differentiation. On the chromatin level, signal transduction leads to changes in epigenetic marks, such as histone post-translational modifications (PTMs), DNA methylation and chromatin accessibility to regulate gene expression. Crosstalk between different epigenetic mechanisms, such as that between histone PTMs and DNA methylation, leads to an intricate network of chromatin-binding proteins where pre-existing epigenetic marks promote or inhibit the writing of new marks. The recent technical advances in mass spectrometry (MS) -based proteomic methods and in genome-wide DNA sequencing approaches have broadened our understanding of epigenetic networks greatly. However, further development and wider application of these methods is vital in developing treatments for disorders and pathologies that are driven by epigenetic dysregulation.
AB - Epigenetics, the inheritance of genomic information independent of DNA sequence, controls the interpretation of extracellular and intracellular signals in cell homeostasis, proliferation and differentiation. On the chromatin level, signal transduction leads to changes in epigenetic marks, such as histone post-translational modifications (PTMs), DNA methylation and chromatin accessibility to regulate gene expression. Crosstalk between different epigenetic mechanisms, such as that between histone PTMs and DNA methylation, leads to an intricate network of chromatin-binding proteins where pre-existing epigenetic marks promote or inhibit the writing of new marks. The recent technical advances in mass spectrometry (MS) -based proteomic methods and in genome-wide DNA sequencing approaches have broadened our understanding of epigenetic networks greatly. However, further development and wider application of these methods is vital in developing treatments for disorders and pathologies that are driven by epigenetic dysregulation.
UR - http://www.scopus.com/inward/record.url?scp=85146193220&partnerID=8YFLogxK
U2 - 10.1042/BCJ20220550
DO - 10.1042/BCJ20220550
M3 - Review article
C2 - 36630129
AN - SCOPUS:85146193220
SN - 0264-6021
VL - 480
SP - 57
EP - 85
JO - Biochemical Journal
JF - Biochemical Journal
IS - 1
ER -